21
Dec
2022

Madrigal’s NASH Persistence Pays, Gilead’s Mixed TIGIT Bag, & Zymeworks’ Rebound

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

VIR’s Scangos Retires, Pliant’s IPF Win, & Some Painful Decisions
Concert Gets Acquired, Structure Tees Up IPO, & a Proposed Noncompete Ban
JPM Vibes, Verily Cuts Back, & Eisai’s Transparent Price
J&J Walks Away from Fate, Century Cuts Back, & Moderna’s Strategic Buy